Biogen forecast 2025 profit below Wall Street expectations on Wednesday, hurt by a strong dollar and fierce competition for ...

Ocrevus as a first-line treatment for early relapsing MS is better at delaying disease progression than starting with a less ...

Sales of an Alzheimer’s disease treatment were better than expected, but that and a quarterly beat wasn’t enough to offset ...

On an adjusted basis, Biogen expects 2025 profit between $15.25 and $16.25 per share. It earned $16.47 in 2024 and analysts ...

Prenatal and early life sun exposure is associated with a lower risk for relapse in childhood-onset MS, new findings suggest, ...